http://rdf.ncbi.nlm.nih.gov/pubchem/patent/JP-2006182661-A
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_7e9aee13868bfedebe2df1f13cda5490 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-395 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-53 |
| filingDate | 2004-12-27-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_342dfe078cf0e4242f55b0df2ee51fee http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_5d6e636cc3eeab2afa8f23fe5e2758a5 |
| publicationDate | 2006-07-13-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | JP-2006182661-A |
| titleOfInvention | Lung cancer immunotherapy agent |
| abstract | Since long-term cure cannot be expected only by conventional chemotherapy, establishment of immunotherapy as a new treatment method having a different mechanism of action from conventional anticancer agents is desired. The establishment of immunotherapy for cancer using safe, effective, and homogeneous antigens is expected in order to overcome the current situation without solid treatment for the treatment and prevention of recurrence of solid cancers such as advanced lung cancer. An amino acid sequence of an immunologically active domain derived from a human myeloma HM1.24 protein antigen, an antibody against a peptide comprising Leu Glu Gly Glu Ile Thr Thr Leu Asn His Lys Leu; ADCC (antibody-dependent cellular cytotoxicity by the antibody) ) Cancer immunotherapeutic agents based on inducing action; cancer diagnostic agents using the antibodies, and the like. [Selection] Figure 1 |
| isCitedBy | http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2015083791-A1 |
| priorityDate | 2004-12-27-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 51.